Your browser is no longer supported. Please, upgrade your browser.
KemPharm, Inc.
Index- P/E- EPS (ttm)-3.98 Insider Own0.10% Shs Outstand35.22M Perf Week-13.02%
Market Cap269.95M Forward P/E26.48 EPS next Y0.29 Insider Trans56.15% Shs Float31.15M Perf Month-1.29%
Income-65.10M PEG- EPS next Q-0.05 Inst Own25.80% Short Float9.79% Perf Quarter-20.74%
Sales28.40M P/S9.51 EPS this Y75.80% Inst Trans-10.70% Short Ratio6.77 Perf Half Y-32.39%
Book/sh3.74 P/B2.05 EPS next Y135.40% ROA-68.90% Target Price19.00 Perf Year26.32%
Cash/sh3.74 P/C2.05 EPS next 5Y- ROE-92.80% 52W Range5.85 - 18.15 Perf YTD-11.83%
Dividend- P/FCF- EPS past 5Y51.40% ROI-242.40% 52W High-57.69% Beta3.14
Dividend %- Quick Ratio36.40 Sales past 5Y- Gross Margin- 52W Low31.28% ATR0.54
Employees22 Current Ratio36.40 Sales Q/Q5.30% Oper. Margin-30.50% RSI (14)38.96 Volatility6.78% 6.70%
OptionableYes Debt/Eq0.00 EPS Q/Q92.70% Profit Margin- Rel Volume1.24 Prev Close7.68
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume450.77K Price7.68
Recom2.50 SMA20-11.07% SMA50-9.44% SMA200-21.85% Volume0 Change0.00%
Mar-04-21Downgrade H.C. Wainwright Buy → Neutral $24 → $12
Jan-25-21Initiated ROTH Capital Buy $28
Jan-19-22 04:21PM  
Jan-12-22 07:30AM  
Jan-11-22 07:30AM  
Jan-06-22 07:30AM  
Dec-28-21 08:40AM  
Dec-20-21 07:30AM  
Dec-14-21 07:30AM  
Dec-13-21 04:05PM  
Dec-07-21 07:34AM  
Nov-19-21 08:46AM  
Nov-10-21 04:05PM  
Nov-05-21 07:30AM  
Nov-03-21 09:22AM  
Oct-27-21 07:30AM  
Oct-20-21 07:30AM  
Oct-19-21 07:30AM  
Sep-27-21 07:30AM  
Sep-23-21 07:30AM  
Sep-09-21 07:30AM  
Aug-18-21 04:45PM  
Aug-12-21 04:05PM  
Aug-05-21 07:30AM  
Jul-21-21 08:30AM  
Jun-29-21 09:01AM  
Jun-18-21 04:01PM  
Jun-16-21 07:30AM  
Jun-09-21 07:30AM  
Jun-03-21 07:30AM  
May-26-21 07:30AM  
May-13-21 04:05PM  
May-07-21 07:30AM  
May-06-21 04:30PM  
Apr-21-21 04:45PM  
Apr-09-21 08:08AM  
Mar-17-21 08:30AM  
Mar-11-21 04:25PM  
Mar-09-21 07:30AM  
Mar-05-21 08:15PM  
Mar-04-21 04:41PM  
Mar-03-21 01:00PM  
Mar-02-21 11:31PM  
Feb-28-21 10:54AM  
Feb-27-21 11:58AM  
Feb-05-21 08:30PM  
Jan-27-21 08:30AM  
Jan-14-21 07:30AM  
Jan-13-21 07:30AM  
Jan-08-21 08:30AM  
Dec-23-20 06:11PM  
Dec-22-20 07:30AM  
Dec-02-20 07:30AM  
Nov-30-20 07:30AM  
Nov-23-20 04:30PM  
Nov-18-20 08:30AM  
Oct-29-20 04:05PM  
Oct-22-20 07:30AM  
Aug-14-20 07:30AM  
Aug-12-20 04:05PM  
Jun-21-20 10:06PM  
May-04-20 08:00AM  
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tierney David SDirectorNov 30Buy7.792,00015,5783,835Nov 30 04:10 PM
Pascoe Richard WExecutive ChairmanNov 30Buy7.881,50011,8223,285Nov 30 07:42 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerNov 18Buy8.295104,2285,240Nov 18 04:57 PM
Mickle Travis CPresident & CEONov 18Buy8.232,25018,51636,521Nov 23 04:03 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 29Buy9.382152,0174,730Sep 29 04:10 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 20Buy8.599358,0284,515Sep 20 05:03 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 01Buy9.112302,0943,580Sep 01 04:04 PM
Mickle Travis CPresident & CEOAug 30Buy8.925,00044,60834,271Aug 30 05:09 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerJun 23Buy14.11751,0583,350Jun 24 04:22 PM
Mickle Travis CPresident & CEOJun 14Buy14.431,50021,645119,507Jun 14 04:37 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerMay 27Buy9.851501,4783,275May 27 05:50 PM
Braun Samuel J10% OwnerMay 13Buy8.5510,00085,5003,070,000May 17 04:42 PM